News

Cardiobridge, VAD, heart pump, hemodynamic support

The Heart Failure 2013 LA meeting will include a showcase of several startup companies offering innovative new approaches to address heart and cardiovascular disease.

January 31, 2013 — Belgian biotechnology company Cardio3 BioSciences (C3BS) announced it has received authorization to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-...

2012 Top 10 Advances in Heart Disease and Stroke Research

Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top...

Cardiac Stem Cells Regeneration Therapy Structural Heart

Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the...

June 22, 2012 — The University of Miami Miller School of Medicine’s Interdisciplinary Stem Cell Institute (ISCI) announced that it received a $10 million grant from The Starr...

June 1, 2012 — LoneStar Heart Inc. announced the advancement of a new therapeutic strategy aimed at genetic reprogramming of cardiac fibroblasts into functioning heart muscle cells to treat damage...

A late-breaking stem cell trial presented at the American College of Cardiology (ACC) Annual Scientific Session showed only minor improvement in heart pumping capability between baseline and...

March 19, 2012 – Individuals suffering from chronic heart failure (CHF) can look forward to the appearance of many new drug options over the next few years and place hope in a cure through future...

March 5, 2012 — Baxter International Inc. announced that it initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (individual’s own) CD34+ stem cells...

January 26, 2012 — Amorcyte LLC, a NeoStem company, announced the enrollment of the first patient in the Amorcyte PreSERVE Phase II trial for acute myocardial infarction. The study is a...

January 13, 2012 — Amorcyte Inc., a NeoStem Inc. company, announced the expansion of intellectual property protection around its lead product candidate, AMR-001, with the grant of U.S. patent...

December 20, 2011 – After a heart attack, the portions of the heart damaged by a lack of oxygen become scar tissue. Researchers have long sought ways to avoid this scarring, which can harden the...

December 20, 2011 –– Howie Lindeman was facing the loss of his career and Neim Malo wasn’t supposed to see 2011. They were each treated for heart disease years ago using their own stem cells to...

December 5, 2011 – University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance…just not as they originally thought.

 

November 18, 2011 – CorMatrix Cardiovascular Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company full investigational device exemption (IDE)...

November 16, 2011 — Heart failure patients with a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that infused them with...

October 24, 2011 — NeoStem Inc. and Amorcyte Inc announced the closing of their previously publicized merger transaction following approval by the shareholders of both companies on Oct. 14, 2011....

September 27, 2011 — A team of physicians, engineers and materials scientists at Children's Hospital Boston and the Massachusetts Institute of Technology (MIT) have created cardiac patches, with...

September 14, 2011 — The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded a $12.8 million program project grant to Roberto Bolli, M.D., for...

September 6, 2011 — Mesoblast Ltd. announced it received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 European clinical trial for Revascor, its...